Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:PDDPF) CEO Ken d’Entremont tells Proactive the specialty pharmaceutical company posted record revenue of C$27.5 million during its fiscal first-quarter thanks to strong sales of its four leading drug products.
d’Entremont says he sees because the firm's portfolio of biggest assets are its strongest, so he sees the firm continuing strong growth going forward.
Price: 4.28 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive the group has received a notice of compliance from Health Canada, granting the company approval to market its tumor imaging agent Gleolan in the country. d’Entremont says with Gleolan, which is essentially...
Prev article
